PFE

In the past six months (April-October 2026), Pfizer's stock hit a 22-month high in September 2026, but subsequently decreased to a 4-week low in mid-September and a 6-week low by early October. Key events included Q1 and Q2 2026 earnings reports, with Q2 exceeding revenue expectations and leading to a slight lift in full-year guidance. The stock was influenced by a Florida Attorney General lawsuit concerning COVID-19 vaccine safety claims, but also supported by positive Phase 2 data for tilrekimig and advancements in its oncology, obesity, and RSV trials. Pfizer also declared its fourth-quarter 2026 dividend, with its dividend yield noted as attractive for income investors.